Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer

Massimo Maffezzini, Fabio Campodonico, Giacomo Capponi, Giorgio Canepa, Stefania Casazza, Roberto Bandelloni, Stefania Tamagno, Matteo Puntoni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: To evaluate the potential contribution of a fluorescent in situ hybridization (FISH) as prognostic indicator of the risk of recurrence or progression in patients undergoing follow-up for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: A total of 126 consecutive patients with a history of NMIBC being followed-up with urinary cytology and cystoscopy at a referral centre were studied. Patients with carcinoma in situ, or tumour stage higher than pT1 were excluded. A UroVysion FISH kit was used to detect four chromosomal abnormalities, specifically, locus 9p21, Ch 3, 7, and 17. Three FISH patterns were defined: negative; low-risk positive, i.e. positive staining for 9p21 and/or Ch3 abnormalities; and high-risk positive, i.e. positive staining for Ch7 andlor 17. Results: Overall 73 out of 126 patients (57.9%) had a positive urinary FISH test. After a median time of 14 months, 46 FISH-positive patients underwent recurrence (36.5%) and in 15 patients there was progression of disease (11.9%). Among positive patients, the low-risk category was found in 34, and the high-risk in 39. Low-risk FISH-positive patients had a higher rate of recurrence as compared to FISH-negative patients, with a hazard ratio (HR) of 1.6. The recurrence rate was even greater in patients with a high-risk positive test, with an HR of 1.9. The limitation of the study was that the impact of intravesical treatment was not assessed. Conclusion: The urinary FISH test can be used as an aid in predicting the risk of recurrence during follow-up of patients with history of NMIBC.

Original languageEnglish
Pages (from-to)4761-4765
Number of pages5
JournalAnticancer Research
Volume30
Issue number11
Publication statusPublished - Nov 2010

Fingerprint

Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Recurrence
Staining and Labeling
Cystoscopy
Carcinoma in Situ
Chromosome Aberrations
Cell Biology
Disease Progression
Referral and Consultation

Keywords

  • Bladder caner
  • Prognosis
  • Recurrence
  • Urinary fish test
  • UroVysion assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maffezzini, M., Campodonico, F., Capponi, G., Canepa, G., Casazza, S., Bandelloni, R., ... Puntoni, M. (2010). Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Research, 30(11), 4761-4765.

Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. / Maffezzini, Massimo; Campodonico, Fabio; Capponi, Giacomo; Canepa, Giorgio; Casazza, Stefania; Bandelloni, Roberto; Tamagno, Stefania; Puntoni, Matteo.

In: Anticancer Research, Vol. 30, No. 11, 11.2010, p. 4761-4765.

Research output: Contribution to journalArticle

Maffezzini, M, Campodonico, F, Capponi, G, Canepa, G, Casazza, S, Bandelloni, R, Tamagno, S & Puntoni, M 2010, 'Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer', Anticancer Research, vol. 30, no. 11, pp. 4761-4765.
Maffezzini M, Campodonico F, Capponi G, Canepa G, Casazza S, Bandelloni R et al. Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Research. 2010 Nov;30(11):4761-4765.
Maffezzini, Massimo ; Campodonico, Fabio ; Capponi, Giacomo ; Canepa, Giorgio ; Casazza, Stefania ; Bandelloni, Roberto ; Tamagno, Stefania ; Puntoni, Matteo. / Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. In: Anticancer Research. 2010 ; Vol. 30, No. 11. pp. 4761-4765.
@article{b1090a1a15dc46a3b8e74eec50e750ab,
title = "Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer",
abstract = "Aim: To evaluate the potential contribution of a fluorescent in situ hybridization (FISH) as prognostic indicator of the risk of recurrence or progression in patients undergoing follow-up for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: A total of 126 consecutive patients with a history of NMIBC being followed-up with urinary cytology and cystoscopy at a referral centre were studied. Patients with carcinoma in situ, or tumour stage higher than pT1 were excluded. A UroVysion FISH kit was used to detect four chromosomal abnormalities, specifically, locus 9p21, Ch 3, 7, and 17. Three FISH patterns were defined: negative; low-risk positive, i.e. positive staining for 9p21 and/or Ch3 abnormalities; and high-risk positive, i.e. positive staining for Ch7 andlor 17. Results: Overall 73 out of 126 patients (57.9{\%}) had a positive urinary FISH test. After a median time of 14 months, 46 FISH-positive patients underwent recurrence (36.5{\%}) and in 15 patients there was progression of disease (11.9{\%}). Among positive patients, the low-risk category was found in 34, and the high-risk in 39. Low-risk FISH-positive patients had a higher rate of recurrence as compared to FISH-negative patients, with a hazard ratio (HR) of 1.6. The recurrence rate was even greater in patients with a high-risk positive test, with an HR of 1.9. The limitation of the study was that the impact of intravesical treatment was not assessed. Conclusion: The urinary FISH test can be used as an aid in predicting the risk of recurrence during follow-up of patients with history of NMIBC.",
keywords = "Bladder caner, Prognosis, Recurrence, Urinary fish test, UroVysion assay",
author = "Massimo Maffezzini and Fabio Campodonico and Giacomo Capponi and Giorgio Canepa and Stefania Casazza and Roberto Bandelloni and Stefania Tamagno and Matteo Puntoni",
year = "2010",
month = "11",
language = "English",
volume = "30",
pages = "4761--4765",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer

AU - Maffezzini, Massimo

AU - Campodonico, Fabio

AU - Capponi, Giacomo

AU - Canepa, Giorgio

AU - Casazza, Stefania

AU - Bandelloni, Roberto

AU - Tamagno, Stefania

AU - Puntoni, Matteo

PY - 2010/11

Y1 - 2010/11

N2 - Aim: To evaluate the potential contribution of a fluorescent in situ hybridization (FISH) as prognostic indicator of the risk of recurrence or progression in patients undergoing follow-up for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: A total of 126 consecutive patients with a history of NMIBC being followed-up with urinary cytology and cystoscopy at a referral centre were studied. Patients with carcinoma in situ, or tumour stage higher than pT1 were excluded. A UroVysion FISH kit was used to detect four chromosomal abnormalities, specifically, locus 9p21, Ch 3, 7, and 17. Three FISH patterns were defined: negative; low-risk positive, i.e. positive staining for 9p21 and/or Ch3 abnormalities; and high-risk positive, i.e. positive staining for Ch7 andlor 17. Results: Overall 73 out of 126 patients (57.9%) had a positive urinary FISH test. After a median time of 14 months, 46 FISH-positive patients underwent recurrence (36.5%) and in 15 patients there was progression of disease (11.9%). Among positive patients, the low-risk category was found in 34, and the high-risk in 39. Low-risk FISH-positive patients had a higher rate of recurrence as compared to FISH-negative patients, with a hazard ratio (HR) of 1.6. The recurrence rate was even greater in patients with a high-risk positive test, with an HR of 1.9. The limitation of the study was that the impact of intravesical treatment was not assessed. Conclusion: The urinary FISH test can be used as an aid in predicting the risk of recurrence during follow-up of patients with history of NMIBC.

AB - Aim: To evaluate the potential contribution of a fluorescent in situ hybridization (FISH) as prognostic indicator of the risk of recurrence or progression in patients undergoing follow-up for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: A total of 126 consecutive patients with a history of NMIBC being followed-up with urinary cytology and cystoscopy at a referral centre were studied. Patients with carcinoma in situ, or tumour stage higher than pT1 were excluded. A UroVysion FISH kit was used to detect four chromosomal abnormalities, specifically, locus 9p21, Ch 3, 7, and 17. Three FISH patterns were defined: negative; low-risk positive, i.e. positive staining for 9p21 and/or Ch3 abnormalities; and high-risk positive, i.e. positive staining for Ch7 andlor 17. Results: Overall 73 out of 126 patients (57.9%) had a positive urinary FISH test. After a median time of 14 months, 46 FISH-positive patients underwent recurrence (36.5%) and in 15 patients there was progression of disease (11.9%). Among positive patients, the low-risk category was found in 34, and the high-risk in 39. Low-risk FISH-positive patients had a higher rate of recurrence as compared to FISH-negative patients, with a hazard ratio (HR) of 1.6. The recurrence rate was even greater in patients with a high-risk positive test, with an HR of 1.9. The limitation of the study was that the impact of intravesical treatment was not assessed. Conclusion: The urinary FISH test can be used as an aid in predicting the risk of recurrence during follow-up of patients with history of NMIBC.

KW - Bladder caner

KW - Prognosis

KW - Recurrence

KW - Urinary fish test

KW - UroVysion assay

UR - http://www.scopus.com/inward/record.url?scp=78650239452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650239452&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 4761

EP - 4765

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -